Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Equipped with most advanced Distributed Control System (DCS) automation technology, the facility has been set up with an investment of Rs. 200 crore
Profit after tax (before exceptional items) up 23% to Rs 215 crores
India confronts alarming rates of eye disorders, propelling the urgency of eyecare awareness
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
Unfortunate to see PM’s ‘Make in India’ dream being bulldozed
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Subscribe To Our Newsletter & Stay Updated
